

1 Next-Generation Sequencing Could be a Promising Diagnostic  
2 Approach for Pathogen Detection: Pathogenic Analysis of Pediatric  
3 Bacterial Meningitis by Next-Generation Sequencing Technology  
4 Directly from Cerebrospinal Fluid Specimens

5 Ling-yun Guo<sup>1, 2</sup>, Yong-jun Li<sup>3</sup>, Lin-lin Liu<sup>1</sup>, Hong-long Wu<sup>4,5</sup>, Jia-li Zhou<sup>4</sup>, Ye Zhang<sup>1</sup>,  
6 Wen-ya Feng<sup>1</sup>, Liang Zhu<sup>1</sup>, Bing Hu<sup>1</sup>, Hui-li Hu<sup>1</sup>, Tian-ming Chen<sup>1</sup>, Xin Guo<sup>1</sup>, He-ying  
7 Chen<sup>1</sup>, Yong-hong Yang<sup>2\*</sup> and Gang Liu<sup>1\*</sup>

8 1. Key Laboratory of Major Diseases in Children, Ministry of Education, Department  
9 of Infectious Diseases, Beijing Children's Hospital, Capital Medical  
10 University, National Center for Children's Health, China

11 2. Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Key Laboratory  
12 of Major Diseases in Children, Ministry of Education, National Clinical Research  
13 Center for Respiratory Diseases, National Key Discipline of Pediatrics (Capital  
14 Medical University), Beijing Pediatric Research Institute, Beijing Children's Hospital,  
15 Capital Medical University, National Center for Children's Health, China

16 3. BGI Genomics Co., Ltd.

17 4. Binhai Genomics Institute, Tianjin Translational Genomics Center, BGI-Tianjin,  
18 BGI-Shenzhen, Tianjin, China

19 5. Wuhan National Laboratory for Optoelectronics, Huazhong University of Science

20 and Technology, Wuhan, Hubei, China

21 \*Prof. Y. H. Y and G.L. are co-corresponding authors and contributed equally to this

22 work.

23 **Address for correspondence**

24 Prof. Gang LIU

25 Beijing Children's Hospital Affiliated with Capital Medical University

26 No. 56 Nan Lishi Road

27 Beijing 100045, China

28 Tel: 86-10-59617012

29 E-mail: liugangbch@sina.com

30 **Keywords** Bacterial meningitis, Pediatric, Cerebrospinal fluid, Next-generation

31 sequencing

32 **Running title** Pathogenic Analysis of Bacterial Meningitis by NGS

33 **Summary** We conducted the study for the identification of microorganisms by

34 next-generation sequencing directly from CSF samples of pediatric bacterial meningitis

35 patients. And the study showed that NGS could be a promising alternative diagnostic

36 approach for bacterial meningitis in pediatric population.

## 37 **Abstract**

38 **Background.** Bacterial meningitis remains one of the major challenges in infectious  
39 diseases, leading to sequel in many cases. A prompt diagnosis of the causative  
40 microorganism is critical to significantly improve outcome of bacterial meningitis. Although  
41 various targeted tests for cerebrospinal fluid (CSF) samples are available, it is a big  
42 problem for the identification of etiology of bacterial meningitis.

43 **Methods.** Here we describe the use of unbiased sequence analyses by next-generation  
44 sequencing (NGS) technology for the identification of infectious microorganisms from  
45 CSF samples of pediatric bacterial meningitis patients in the Department of Infectious  
46 Diseases from Beijing Children's Hospital.

47 **Results.** In total, we had 99 bacterial meningitis patients in our study, 55 (55.6%) of these  
48 were etiologically confirmed by clinical microbiology methods. Combined with NGS, 68  
49 cases (68.7%) were etiologically confirmed. The main pathogens identified in this study  
50 were *Streptococcus pneumoniae* (n=29), group B streptococcus (n=15), *Staphylococcus*  
51 *aureus* (n=7), *Escherichia coli* (n=7). In addition, two cases with cytomegalovirus infection  
52 and one with *Taenia saginata asiatica* were confirmed by NGS.

53 **Conclusions.** NGS could be a promising alternative diagnostic approach for critically ill  
54 patients suffering from bacterial meningitis in pediatric population.

## 55 BACKGROUND

56 Bacterial meningitis, also known as purulent meningitis, is caused by a variety of pyogenic  
57 infections. Although the incidence in infants and children has decreased since the use of  
58 conjugated vaccines targeting *Haemophilus influenzae type b* (Hib), *Streptococcus*  
59 *pneumoniae* (*S. pneumoniae*) and *Neisseria meningitidis* (*N. meningitidis*), bacterial  
60 meningitis continues to be an important cause of mortality and morbidity in neonates and  
61 children throughout the world [1, 2]. The causative pathogens of bacterial meningitis  
62 depend on different age of the patient and predisposing factors [1-3].

63 Pathogen identification is of paramount importance for bacterial meningitis. At present,  
64 the pathogen of bacterial meningitis is still mainly based on Gram stain and bacterial  
65 culture. However, CSF culture can be negative in children who receive antibiotic treatment  
66 prior to CSF examination [1]. Because of the limitations of clinical laboratory testing, more  
67 than half of the central nervous system infection cases cannot be clearly diagnosed [4].  
68 Although non-culture methods including multiplex PCR and latex agglutination, etc. have  
69 been used in clinical microbiology [1], only one or several specific pathogens could be  
70 targeted by these kinds of technology, let alone rare pathogens.

71 In recent years, the emergence of powerful NGS technology have enabled unbiased  
72 sequencing of biological samples due to its rapid turnaround time [5]. Wilson et  
73 al [6] presented a case of neuroleptospirosis, resulting in a dramatic clinical improvement

74 with intravenous penicillin after identifying leptospira infection in the CSF by unbiased  
75 NGS technology. Unbiased NGS could facilitate identification of all the potential  
76 pathogens in a single assay theoretically [7]. Herpes simplex virus 1, herpes simplex virus 2  
77 and human herpes virus type 3 were detected using NGS technology from four cases with  
78 clinically suspected viral meningoencephalitis respectively. And the results were further  
79 validated using PCR [8]. Further, Yao et al [9] detected *Listeria monocytogenes* in CSF from  
80 three patients with meningoencephalitis by NGS. These reports highlight the feasibility of  
81 applying NGS of CSF as a diagnostic method for central nervous system (CNS) infection.  
82 However, the majority of reports are comprised of single case reports and few studies  
83 have been reported in the application of NGS for pathogen detection from CSF samples of  
84 bacterial meningitis patients, especially in pediatric populations. In this study, we would  
85 like to use the NGS technology to detect directly from the CSF samples of children with  
86 bacterial meningitis and evaluate the feasibility and significance of the NGS technique on  
87 the pathogenic identification of bacterial meningitis.

## 88 **METHODS**

### 89 **Study Population**

90 Cases of bacterial meningitis in patients of age between 29days and 18 years old from  
91 Oct.23<sup>th</sup> 2014 through Dec.31<sup>th</sup> 2016 in the Department of Infectious Diseases, Beijing  
92 Children's Hospital were included. Patients with disagreement to collecting CSF, CSF

93 volume < 1ml and bloody CSF were excluded. This tertiary health care hospital is a  
94 National Children's Medical Center with 970beds that treats more than 3 million  
95 outpatients and 70,000 hospitalized patients every year. Records for all patients including  
96 demographic data, clinical features and laboratory findings were obtained.

### 97 **Diagnosis of bacterial meningitis**

98 Any child with sudden onset of fever (> 38.5°C rectal or 38.0°C axillary) and neck stiffness,  
99 altered consciousness or other meningeal symptoms were considered to be suspected  
100 patients. A case that is laboratory-confirmed [culture method and/ or antigen detection  
101 methods (Alere BinaxNow<sup>®</sup> *Streptococcus pneumoniae* Antigen Card)] by identifying a  
102 bacterial pathogen from CSF or blood in a child with clinical symptoms consistent with  
103 bacterial meningitis is a proven case. Otherwise, a suspected case with CSF examination  
104 showing at least one of the following is a probable case: a turbid CSF appearance,  
105 leukocytosis (> 100 cells/mm<sup>3</sup>), leukocytosis (10-100 cells/ mm<sup>3</sup>) and either elevated  
106 protein (> 100 mg/dl) or decreased glucose level (< 40 mg/dl). These criteria are  
107 consistent with the World Health Organization (WHO) case definition [10].

### 108 **Sample collection**

109 CSF was collected in accordance with standard procedures, snap frozen and stored at -80°  
110 C in Bio bank for Diseases in Children Beijing Children's Hospital, Capital Medical  
111 University.

### 112 **DNA extraction, library construction, and sequencing**

113 DNA was extracted directly from the clinical samples using the TIANamp Micro DNA Kit  
114 (DP316, Tiangen Biotech, Beijing, China). DNA libraries were constructed through end-  
115 repaired adapter added overnight, and by applying polymerase chain reaction  
116 amplification to the extracted DNA. Quality control was carried out using a bioanalyzer  
117 (Agilent 2100, Agilent Technologies, Santa Clara, CA, USA) combined with PCR to  
118 measure the adapters before sequencing. DNA sequencing was then performed using the  
119 BGISEQ-100 platform (BGI-Tianjin, Tianjin, China) <sup>[11]</sup>.

## 120 **Data treatment and analysis**

121 High-quality sequencing data were generated after filtering out low-quality, low-complexity,  
122 and shorter reads. To eliminate the effect of the human sequences, the data mapped to  
123 the human reference genome (hg19) were excluded using a powerful alignment tool  
124 called Burrows-Wheeler Alignment <sup>[12]</sup>. The remaining data were then aligned to the  
125 Microbial Genome Database, which includes bacteria, viruses, fungi, and protozoa.  
126 Finally, the mapped data were processed by removing duplicate reads for advanced data  
127 analysis. A no redundant database that included all the published genomes of  
128 microorganisms was downloaded from the National Center for Biotechnology Information  
129 (<ftp://ftp.ncbi.nlm.nih.gov/genomes/>). The depth and coverage of each species were  
130 calculated using Soap Coverage from the SOAP website (<http://soap.genomics.org.cn/>).

## 131 **Ethics Statement**

132 This study was reviewed and approved by the Ethics Committee of Beijing Children's  
133 Hospital Affiliated to Capital Medical University (No.2017-74). Written informed consents  
134 were obtained from all patients or their legal surrogates.

### 135 **Statistical Analysis**

136 Categorical variables were compared using the chi-squared test or Fischer's exact test, as  
137 appropriate. Continuous variables within two groups were compared using the  
138 independent t-test for parametric data and the Mann-Whitney U test for non-parametric  
139 data. *P* values <0.05 were considered statistically significant. All statistical analyses were  
140 conducted using SPSS 17.0(SPSS Inc. USA).

## 141 **RESULTS**

### 142 **Demographics**

143 A total of 99 cases were finally included in our study. Among them, 68 (68.7%) cases were  
144 male, 31 (31.3%) females, and a male to female ratio of 2.2: 1. The median age of onset  
145 was 5.7 months. These cases were classified into four age groups: 73 (73.8%) patients  
146 aged 29 days to 1 year, 1-year-old to 2 years old group (n = 13, 13.1%); 2 years old to 5  
147 years old group (n = 4, 4.0%); greater than 5 years old group (n = 9, 10.0%). 57.6% (57  
148 cases) of children were from rural areas. The median time to diagnose bacterial meningitis  
149 was 3 (2-7) days.

### 150 **Bacterial pathogen detection by clinical microbiology methods**



151 55 cases (55.6%) had positive clinical pathogen detections. Among them, 33 (33.3%)  
152 cases were positive from the CSF culture, 32 (32.3%) cases were positive from the blood  
153 culture, and 13 (13.1%) cases of them were positive both from CSF and blood culture. 21  
154 (21.2%) cases had positive results of Alere BinaxNow<sup>®</sup> *Streptococcus pneumoniae*  
155 Antigen test. In terms of pathogen distribution, *S. pneumoniae* infection was the primary  
156 pathogen, 23 (41.8%) cases of children with the presence of this bacterial infection.  
157 Followed by *Streptococcus agalactia* in 11 cases (20.0%), *Escherichia coli* in six cases  
158 (10.9%), *Staphylococcus aureus* in five cases (9.09%), *Listeria monocytogenes* in four  
159 cases (7.3%). There was also one case of *Enterococcus faecalis*, *Streptococcus bacteria*,  
160 *Streptococcus mitis*, *Haemophilus influenzae*, *Streptococcus bovis*, and *Eickhelium*  
161 *echinobacterium*, respectively.

## 162 NGS results

### 163 NGS overall data

164 99 samples of cerebrospinal fluid were detected by NGS, and generated 2, 852,780,707  
165 raw reads. After the removal the short read length (length  $\leq$  35bp), the low complexity  
166 and low-quality reads, 2,846,199,682 were obtained. The average number of raw reads  
167 and clean reads for each sample were 28,815,967 and 28,749,492, respectively. The  
168 mean rate of 95.35% mapped to the human genome. And finally, the average ratios of the  
169 reads mapped to bacterial, viral and fungal genome were 0.0216%, 0.000015% and  
170 0.000405%, respectively.

## 171 **Determination of pathogens by NGS technology**

172 A total of 10 kinds of pathogenic microorganisms were determined by NGS. There were  
173 six kinds of Gram-positive bacteria, two kinds of Gram-negative bacteria, one kind of virus  
174 (two cases of cytomegaloviruses) and one kind of parasite (*Taenia saginata*) among them.  
175 Among the pathogenic bacteria, *S. pneumoniae* was still the predominant pathogen  
176 accounting for 51.2% of bacteria, followed by *Streptococcus agalactiae* in 19.5% of  
177 bacteria, *Staphylococcus aureus* in 7.3%, *Enterococcus faecalis* in 7.3%, *Escherichia coli* in  
178 4.9%, *Listeria monocytogenes* in 4.9%. The coverage, depth and unique reads of different  
179 species were between 0.0046% -68%, 1-2, 2-67550, respectively. (Table 1 and Figure 1).

## 180 **Combination of NGS and clinical microbiology methods**

181 Combined with clinical pathogen detection methods and NGS technology, 76 kinds of  
182 microorganisms were determined while 44 of them were detected by NGS and 55 of them  
183 were detected by clinical microbiology methods. A total of 68 cases (68.7%) had positive  
184 pathogens, of which 67 cases (67.7%) had positive bacterial pathogen results. NGS  
185 increased the positive rate of pathogen detection by 13.1% (the positive rate of pathogen  
186 detection increased from 55.6% to 68.7%) and 23.6% of the pathogens were  
187 independently detected by the NGS method.

188 In terms of analyzing specific pathogen, a total of 29 *S. pneumoniae* were detected by  
189 combination methods, while six of them were independently detected by the NGS method;  
190 a total of 15 *S. agalactiae* were detected by combination methods, while four of them were

191 independently detected by the NGS method; a total of seven *Staphylococcus aureus* were  
192 detected by combination methods, and two of them were independently detected by the  
193 NGS method; a total of seven *Escherichia coli* were detected by combination methods,  
194 and one of them were independently detected by the NGS method(Figure 2).Overall, *S.*  
195 *pneumoniae* (n=29, 39.7%), *S. agalactiae* (n=15, 20.5%), *Staphylococcus aureus* (n=7,  
196 9.6%), and *Escherichia coli* (n=7, 9.6%) were the most frequently detected pathogens in  
197 this study. In addition, there were four cases of *Listeria monocytogenes* (5.5%), three of  
198 *Enterococcus faecium* (4.1%) (Figure 3).

#### 199 **Comparison of the NGS-positive and NGS-negative groups**

200 The NGS-positive group comprised 41 (41.4%) patients who had positive bacterial results  
201 by NGS. The NGS-negative group comprised 58 cases. Patients in the NGS-positive  
202 group had generally shorter days in terms of duration from onset to the sample collection  
203 (median days 15 vs. 31 days,  $P = 0$ ) and shorter onset days than those in the  
204 pathogen-negative group (median days 6 vs. 25 days,  $P = 0.005$ ). With regard to blood  
205 inflammatory indices, patients in the NGS-positive group were frequently found to have  
206 higher neutrophils (66.7% vs. 54.7%,  $P = 0.002$ ) than those in the NGS- negative group.  
207 The two groups of patients did not differ significantly in age or diagnosis duration. In  
208 addition, there was no significant difference in the simultaneously CSF WBC count  
209 between members of these two groups, and they had CSF similar protein and glucose  
210 levels (Table 2).

## 211 **Discussion**

212 It can be seen from our data that NGS can improve the overall positive rate of pathogen  
213 detection, especially in clinically negative samples. The results of clinical pathogen  
214 detection and NGS pathogen showed that 68 cases (68.7%) were positive in 99 cases of  
215 bacterial meningitis, 67 cases (67.7%) were positive for bacterial pathogens. Further  
216 analysis of data, we found that 13 cases had positive pathogens in the group of clinical  
217 microbiological-negative group (44 cases). NGS increased the positive rate of pathogen  
218 detection by 13.1% (the positive rate of pathogen detection increased from 55.6% to  
219 68.7%). Although there are few results in terms of NGS using in the large population of  
220 bacterial meningitis, there is increasing evidence of a role for NGS in the work-up of  
221 undiagnosed encephalitis and meningitis [13]. Brown JR et al recommend NGS should be  
222 considered as a front-line diagnostic test in chronic and recurring encephalitis. And the  
223 results in our study consistent with a study of NGS which conducted in patients with sepsis,  
224 and detectability were significantly increased from 12.82% to 30.77% [14]. It indicates that  
225 an NGS-based approach has great potential to detect causative pathogens of infectious  
226 diseases.

227 Unbiased NGS technology amplifies all nucleic acids present in a clinical sample,  
228 including both host and microbes without requiring primers for targeted amplification, and  
229 can potentially generate microbial sequence data offering the capability of identifying a  
230 variety of organisms- bacteria, virus, fungi, or parasite [15]. As can be seen from our study,

231 95.35% of the NGS sequencing data were compared to the human genome, whereas less  
232 than <1% to the pathogen genome. Previous studies referred to the application of NGS in  
233 clinical pathogen detection showed similar situation in both bacterial and/or virus  
234 infections <sup>[14]</sup>. In addition, this method clearly shows the advantages of recognizing  
235 multi-pathogens infection. Alexander and other researchers have emphasized that it is  
236 important to rich the genome database in order to enhance the completeness analysis of  
237 the results. If you only add a part of gene sequence to the database, this may reduce the  
238 sensitivity of the assay <sup>[16, 17]</sup>. Therefore, in order to give full play to the potential of NGS, it  
239 is necessary to set up a well suitable local database and coverage pathogen genome as  
240 much as possible. The results in our study showed that the primary pathogen was still *S.*  
241 *pneumoniae*. 29 cases of *S. pneumoniae* were detected, accounting for 39.7% of the total  
242 bacterial pathogens. It is worth noting that the second place of the pathogen is *S.*  
243 *agalactiae* in 15 cases, accounting for 20.8% of the total detected bacterial pathogens.  
244 This is consistent with the rising trend of *S. agalactiae*, which has been reported in our  
245 previous study <sup>[18]</sup>. Furthermore, we found two cases with cytomegaloviruses infection and  
246 one patient with *Taenia saginata*. These three patients were diagnosed as bacterial  
247 meningitis definitely, thus NGS clearly shows the advantages of recognizing  
248 multi-pathogens infection. However, the role of other microorganisms, e.g.  
249 cytomegaloviruses and *Taenia saginata*, in the process of bacterial meningitis should be  
250 further discussed in the future.

251 The interpretation of the NGS results is of great important and difficult in some situations.  
252 NGS pathogen detection usually obtains a variety of suspected pathogens gene  
253 sequences, and how to distinguish between pathogens and contaminating "background  
254 bacteria" becomes critical. Procedures including clinical specimen collection, sample  
255 preservation, transportation and the experimental procedures, may cause pollution and  
256 lead to contaminate the specimen mixed with so called "background" microbial gene  
257 sequence, which may affect the NGS data analysis [15,19,20], resulting in false positive  
258 results and hinder the doctors. Similar to previous reports, we found that the most  
259 common background bacterium was *Propionibacterium acnes* in our study (data not  
260 shown here) [14].

261 We compared NGS-positive and NGS-negative groups, and analyzed factors that could  
262 affect NGS results. Patients in the NGS-positive group had generally shorter days in terms  
263 of duration from onset to the sample collection (median days 15 vs. 31 days,  $P = 0$ ) and  
264 shorter onset days than those in the pathogen-negative group (median days 6 vs. 25 days,  
265  $P = 0.005$ ). In terms of time between two groups, we found that 32 (94.12%) of the  
266 samples were less than 42 days (data did not show) in the NGS-positive group. Only 2  
267 patients received cerebrospinal fluid samples  $> 42$  days. It indicated that the earlier  
268 detected the more positive possibility. In addition, it is noting that there was no significant  
269 difference in the simultaneously CSF WBC count between two groups, and they had CSF  
270 similar protein and glucose levels. These altogether suggests that the original severity of

271 inflammation, not the inflammation status while the simultaneously NGS detects might  
272 determine the NGS results. The impact of time on the results of NGS may be related to the  
273 nucleic acid content in the specimen, but this is still to be further validated by future clinical  
274 studies of large samples.

275 To our knowledge, the present study is one of the largest case series of using NGS in  
276 (pediatric) bacterial meningitis patients around world. However, this study has some  
277 limitations. It was a single center, hospital-based retrospective design, which introduces  
278 the possibility of unrecognized biases, incomplete data collection. Thus, further  
279 prospective multi-center studies are necessary to enrich the generalizability of NGS  
280 technology using in pediatric bacterial meningitis.

281 In summary, our study demonstrated the comprehensive diagnostic ability of NGS in  
282 identifying etiology of bacterial meningitis and the factors associated with the NGS results.  
283 As a new technology of detection, NGS could be a promising alternative diagnostic  
284 powerful tool for pathogen detection allowing us to detect organisms in critically ill patients  
285 suffering from bacterial meningitis.

## 286 **Conclusions**

287 NGS could be a promising alternative diagnostic approach for critically ill patients  
288 suffering from bacterial meningitis in pediatric population.

## 289 **Notes**

290 **Funding.** This work was supported by no foundation.

291 **Conflict of interest.** No conflicts of interest are declared with regard to this article.

292 **Acknowledgements.** We would like to thank Professor Hongzhi Guan at the Department of  
293 Neurology, Peking Union Medical College Hospital for his assistance and valuable  
294 suggestions of this study. we would like to thank Bio bank for Diseases in Children Beijing  
295 Children's Hospital, Capital Medical University for their contribution of storing the CSF  
296 samples with standard procedures. In addition, we would like to thank Xue Yao at  
297 BGI-Shenzhen for her coordination in this study.

298 **Author contributors.** All of the authors had access to the full dataset (including the  
299 statistical reports and tables) and take responsibility for the integrity of the data and the  
300 accuracy of the data analysis. GLY, LYJ, YYH and LG conceived and designed the study.  
301 GLY, LLL, ZY, FWY, ZL, HB, HHL, CHY, CTM, GX were involved in case and sample  
302 collection, analysis, and interpretation of the data. GLY, LYJ, WHL, ZJL participated in the  
303 laboratory analysis of CSF. GLY wrote the first draft of the paper. GLY, YYH, and LG  
304 reviewed and approved the final report.



305 **Reference**

- 306 1. Kim KS. Acute bacterial meningitis in infants and children. *Lancet Infect Dis* **2010**; 10:  
307 32–42.
- 308 2. Le Saux N; Canadian Paediatric Society. Infectious Diseases and Immunization  
309 Committee. Guidelines for the management of suspected and confirmed bacterial  
310 meningitis in Canadian children older than one month of age. *Paediatr Child Health*  
311 **2014**; 19:141-52.
- 312 3. van de Beek D, Cabellos C, Dzupova O, Esposito S, Klein M, Kloek AT, Leib SL,  
313 Mourvillier B, Ostergaard C, Pagliano P, Pfister HW, Read RC, Sipahi OR, Brouwer  
314 MC; ESCMID Study Group for Infections of the Brain (ESGIB).  
315 ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. *Clin*  
316 *Microbiol Infect* **2016**; 22 Suppl 3: S37-62.
- 317 4. Glaser CA, Honarmand S, Anderson LJ, Schnurr DP, Forghani B, Cossen CK,  
318 Schuster FL, Christie LJ, Tureen JH. Beyond viruses: clinical profiles and etiologies  
319 associated with encephalitis. *Clin Infect Dis* **2006**; 43:1565–1577.
- 320 5. Ryan D. Schubert, Michael R. Wilson. A tale of two approaches: how metagenomics  
321 and proteomics are shaping the future of encephalitis diagnostics. *Curr Opin Neurol*  
322 **2015**; 28: 283–287.
- 323 6. Wilson MR, Naccache SN, Samayoa E, Biagtan M, Bashir H, Yu G, Salamat SM,  
324 Somasekar S, Federman S, Miller S, Sokolic R, Garabedian E, Candotti F, Buckley

- 325 RH, Reed KD, Meyer TL, Seroogy CM, Galloway R, Henderson SL, Gern JE, DeRisi  
326 JL, Chiu CY. Actionable diagnosis of neuroleptospirosis by next-generation  
327 sequencing. *N Engl Med* **2014**; 370: 2408-2417.
- 328 7. Naccache SN, Federman S, Veeraraghavan N, Zaharia M, Lee D, Samayoa E,  
329 Bouquet J, Greninger AL, Luk KC, Enge B, Wadford DA, Messenger SL, Genrich GL,  
330 Pellegrino K, Grard G, Leroy E, Schneider BS, Fair JN, Martínez MA, Isa P, Crump  
331 JA, DeRisi JL, Sittler T, Hackett J Jr, Miller S, Chiu CY. A cloud-compatible  
332 bioinformatics pipeline for ultra rapid pathogen identification from next-generation  
333 sequencing of clinical samples. *Genome Res* **2014**;24(7): 1180–1192.
- 334 8. Guan H, Shen A, Lv X, Yang X, Ren H, Zhao Y, Zhang Y, Gong Y, Ni P, Wu H, Zhu Y,  
335 Cui L. Detection of virus in CSF from the cases with meningoencephalitis by  
336 next-generation sequencing. *J Neurovirol* **2016**; 22:240-5.
- 337 9. Yao M, Zhou J, Zhu Y, Zhang Y, Lv X, Sun R, Shen A, Ren H, Cui L, Guan H, Wu H.  
338 Detection of *Listeria monocytogenes* in CSF from Three Patients with  
339 Meningoencephalitis by Next-Generation Sequencing. *J Clin Neurol* **2016**;  
340 12:446-451.
- 341 10. World Health Organization. WHO-recommended standards for surveillance of  
342 selected vaccine-preventable diseases; 2003, May. WHO/V&B/03. 01. Geneva:  
343 WHO; **2013**, Available at: [http://www.measles\\_rubellainitiative.org/  
344 wp-content/uploads/2013/06/WHO-surveillance-standard.pdf](http://www.measles_rubellainitiative.org/wp-content/uploads/2013/06/WHO-surveillance-standard.pdf)

- 345 11. Jeon YJ, Zhou Y, Li Y, Guo Q, Chen J, Quan S, Zhang A, Zheng H, Zhu X, Lin J, Xu  
346 H, Wu A, Park SG, Kim BC, Joo HJ, Chen H, Bhak J. The feasibility study of  
347 non-invasive fetal trisomy 18 and 21 detection with semiconductor sequencing  
348 platform. *PLoS One* 2014; 9: e110240.
- 349 12. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler  
350 transform. *Bioinformatics* 2009; 25:1754-1760.
- 351 13. Brown JR, Bharucha T, Breuer J. Encephalitis diagnosis using metagenomics:  
352 application of next generation sequencing for undiagnosed cases. *J Infect* 2018;  
353 76:225-240.
- 354 14. Long Y, Zhang Y, Gong Y, Sun R, Su L, Lin X, Shen A, Zhou J, Caiji Z, Wang X, Li D,  
355 Wu H, Tan H. Diagnosis of Sepsis with Cell-free DNA by Next-Generation  
356 Sequencing Technology in ICU Patients. *Arch Med Res* 2016; 47:365-371.
- 357 15. Motro Y, Moran-Gilad J. Next-generation sequencing applications in clinical  
358 bacteriology. *Biomol Detect Quantif* 2017; 14:1-6.
- 359 16. Greninger AL, Kevin M, Thelma D, Naccache SN, Scot F, Jerome B, David M, Y  
360 osuke N, Shigeo Y, Carol G. Clinical metagenomic identification of *Balamuthia*  
361 *mandrillaris* encephalitis and assembly of the draft genome: the continuing case for  
362 reference genome sequencing. *Genome Med* 2016; 7: 113.

- 363 17. Lefterova MI, Suarez CJ, Banaei N, Pinsky BA. Next-Generation Sequencing for  
364 Infectious Disease Diagnosis and Management: A Report of the Association for  
365 Molecular Pathology. *J Mol Diagn* **2015**; 17:623-34.
- 366 18. Guo LY, Zhang ZX, Wang X, Ping-ping Zhang, Wei Shi, Kai-hu Yao, Lin-lin Liu, Gang  
367 Liu, Yong-hong Yang. Clinical and pathogenic analysis of 507 children with bacterial  
368 meningitis in Beijing, 2010-2014. *Int J Infect Dis* 2016; 50:38-43.
- 369 19. Lusk RW. Diverse and widespread contamination evident in the unmapped depths of  
370 high throughput sequencing data. *PLoS One* 2014; 9: e110808.
- 371 20. Salter SJ, Cox MJ, Turek EM, Calus ST, Cookson WO, Moffatt MF, Turner P, Parkhill  
372 J, Loman NJ, Walker AW. Reagent and laboratory contamination can critically impact  
373 sequence-based microbiome analyses. *BMC Biol* 2014; 12:87.

374

**Table 1. Pathogenic microorganisms determined by NGS**

<b>Type</b>	<b>Pathogens</b>	<b>No.</b>	<b>Coverage</b>	<b>Depth</b>	<b>Unique Reads</b>
Gram-positive	<i>Streptococcus pneumoniae</i>	21	0.011%-11%	1-1.1	4-1105
bacteria	<i>Streptococcus agalactiae</i>	8	0.0046%-25%	1-1.2	2-12004
	<i>Staphylococcus aureus</i>	3	0.26%-2.4%	1	56-1380
	<i>Enterococcus faecium</i>	3	0.03%-0.74%	1	17-394
	<i>Listeria monocytogenes</i>	2	0.04%-5%	1	8-2561
	<i>Staphylococcus pasteurii</i>	1	20%	1.1	5716
Gram-negative	<i>Escherichia coli</i>	2	0.34%-0.46%	1	32-65
bacteria	<i>Pseudomonas aeruginosa</i>	1	68%	2	67550
Virus	<i>Cytomegalovirus</i>	2	0.45%-1.1%	1	20-49
Parasite	<i>Taenia saginata asiatica</i>	1	0.58%	1	9610
Total		44	0.0046%-68%	1-2	2-67550

375

**Table 2. Comparison of NGS-positive and NGS-negative groups <sup>a</sup>**


Items		NGS-positive <sup>b</sup> (n=41)	NGS-negative (n=58)	<i>P</i>
Age (days)		230(69.5-425)	116.5(65.5-392.5)	0.379
Duration from onset to the sample collection (days)		15(8.5-28)	31(17-45)	0
Onset (days)		6(4-21)	25(4-41)	0.005
Diagnosis Duration (days)		4(2-8)	3(1-6.75)	0.66
Peripheral	WBC( $\times 10^9/L$ )	17.3 $\pm$ 11.9	13.5 $\pm$ 7.3	0.074
Blood	neutrophils (%)	66.7 $\pm$ 15.7	54.7 $\pm$ 20.2	0.002
	hemoglobin (g/L)	104.0 $\pm$ 19.9	103.8 $\pm$ 17.2	0.943
	C-reactive protein (mg/L)	29 (11.0-101.1)	27.7(8-108.5)	0.393
1 <sup>st</sup> CSF	WBC ( $\times 10^6/L$ )	910(336-2825)	403(98-2040)	0.125
	multinuclear cells (%)	70(38.75-85)	60(22-75)	0.165
	monocyte (%)	24.3(15-55.5)	38.5(23.0-75.0)	0.099
	protein (mg/L)	1278(837-2234)	1340(596-1982)	0.485
	glucose (mmol/L)	1.47(0.87-2.74)	2.48(1.02-2.48)	0.12
Simultaneously	WBC ( $\times 10^6/L$ )	10(2-17)	11(2-37)	0.432
CSF <sup>c</sup>	multinuclear cells (%)	10(4-16)	12(5-20)	0.723
	monocyte (%)	20(12-28)	30(15-54)	0.051
	protein (mg/L)	557(296-1149)	594(367-1079)	0.85
	glucose (mmol/L)	2.85(2.43-3.46)	2.90(2.46-3.66)	0.869

376 NGS, next generation sequencing; WBC, white blood cell; CRP, C-reactive protein; CSF,  
377 cerebrospinal fluid.

378 <sup>a</sup> Results are reported as the median (interquartile range), or as the percentage.

379 <sup>b</sup> NGS-positive group refers to the cases who had positive bacterial NGS results.

380 <sup>c</sup> Simultaneously CSF refers to the CSF results by clinical testing at which time CSF is detected  
381 by NGS.



382

383


**Figure 1. The distribution of different bacterial pathogens by NGS**

384 Note: Spn, *Streptococcus pneumoniae*; GBS, *group B Streptococcus*; SA, *Staphylococcus aureus*;

385 Eco, *Escherichia coli*; Li, *Listeria monocytogenes*; Efa, *Enterococcus faecium*; others includes

386 *Pseudomonas aeruginosa* and *Staphylococcus pasteurii*.






387  
388 **Figure 2. Number of different pathogens detected by clinical testings and combination with**  
389 **NGS**

390 Note: Spn, *Streptococcus pneumoniae*; GBS, *group B Streptococcus*; SA, *Staphylococcus aureus*;  
391 Eco, *Escherichia coli*; Li, *Listeria monocytogenes*; others includes *Enterococcus faecalis*,  
392 *Enterococcus faecalis*, *Streptococcus pyogenes*, *Streptococcus mitis*, *Streptococcus bovis*,  
393 *Haemophilus influenza*, *Streptococcus bovis*, *Eikenella corrodens*, *Pseudomonas aeruginosa* and  
394 *Staphylococcus pasteurii*, *Cytomegalovirus* and *Taenia saginata asiatica*

395



396

397 **Figure 3. The distribution of bacterial pathogens by combination of clinical methods and**

398 **NGS**

399 Note: Spn, *Streptococcus pneumoniae*; GBS, *group B Streptococcus*; SA, *Staphylococcus aureus*;

400 Eco, *Escherichia coli*; Li, *Listeria monocytogenes*; Efa, *Enterococcus faecium*; others including

401 *Enterococcus faecalis*, *Streptococcus pyogenes*, *Streptococcus mitis*, *Haemophilus*

402 *influenza*, *Streptococcus bovis*, *Eikenella corrodens*, *Pseudomonas aeruginosa* and

403 *Staphylococcus pasteurii*; others includes *Enterococcus faecalis*, *Streptococcus*

404 *pyogenes*, *Streptococcus mitis*, *Haemophilus influenza*, *Streptococcus bovis*, *Eikenella corrodens*,

405 *Pseudomonas aeruginosa* and *Staphylococcus pasteurii*